• Informed consent.

• Female patients aged ≥18 years and ≤ 75 years at time of inform consent signature

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Expected survival ≥ 3 months

• Patients must have histologically confirmed diagnosis of HPV-related cervical squamous, or adenocarcinoma, or adenosquamous carcinoma

• FIGO 2018 stage T3a-4a (III-IVA), N1 (positive lymph node metastasis on CT/MRI with short-axis ≥1 cm, or PET-CT showing one or more lymph node metastases with SUVmax ≥2.5), M0

• Has at least one evaluable disease per RECIST 1.1

• Has adequate organ function

‣ Hematology: ANC ≥1.5 ×10⁹/L; platelets ≥100 ×10⁹/L; hemoglobin ≥90 g/L (no blood transfusion or growth factor support within 7 days)

⁃ Renal: CrCl ≥50 mL/min (Cockcroft-Gault formula), urine protein \<2+ or 24h \<1.0 g

⁃ Hepatic: Total bilirubin ≤1.5×ULN; AST and ALT ≤2.5×ULN

⁃ Coagulation: INR and APTT ≤1.5×ULN

⁃ Cardiac: LVEF ≥50%

• Women of childbearing potential: a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug (if the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test must be performed, and the serum result will be considered definitive).If a female participant of childbearing potential engages in sexual activity with a male partner who is not surgically sterile, she must use an acceptable method of contraception starting from screening and agree to continue using the same contraception for 120 days after the last dose of study drug. Whether to discontinue contraception after this period should be discussed with the investigator

• Willingness to comply with the study procedures before study entry